FitzGerald et al. PsA patients with higher levels of IL-23-IL-17 pathway biomarkers more likely to benefit from TYK2i deucravacitinib @RheumNow #ACR22 Abstr#2133 https://t.co/eVq4XQgX5l https://t.co/HZlTS5OZ2s

• Baseline Biomarkers Predict Better Responses to Deucravacitinib, an Oral, Selec…

Fleischmann et al. Safety of TYK2i Deucravacitinib in PsA/PsO in terms of labs. Really no effect on lab values other than increase in trigs. Guess this is why they don't have lab monitoring on label? @RheumNow #ACR22 Abstr#2132 https://t.co/ueIVKQc6jr https://t.co/u99QE71VQ5

• Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor: As A…

Warren et al. TYK2i deucravacitinib in plaque psoriasis at 2 years. Sustained efficacy. No new safety signals seen. @RheumNow #ACR22 Abstr#2134 https://t.co/5SGKKrvwbc https://t.co/ynvfZiOrsp

• Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Resul…

⇧ brain functional connectivity to the insula between the mid-posterior IC & brain areas involved in sensory (thalamus), learning/affective (parahippocampal gyrus), cognitive (prefrontal cortex) pain modulation in PsA. Sunzini F Abs#2256 https://t.co/5TUcOacuIS #ACR22 @RheumNow https://t.co/7IqLYzzpyA

• MRI Spinal Lesions in Patients Without MRI or Radiographic Lesions in the Sacro…

Kavanaugh et al. TYK2i deucravacitinib in PsA. Nice breakdown of MDA and its components over 16 weeks. MDA achieved 23-24% with deucravacitinib at 16 weeks vs 8% with placebo @RheumNow #ACR22 Abstr#2136 https://t.co/9IG8CeZzMh https://t.co/Vg8E20y7Z8

• Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in a Phase 2 T…

Mease et al. TYK2i Deucravacitinib in PsA. Phase 2 RCT 52 week results. PASDAS, DAPSA efficacy maintained through week 52. No new safety concerns. @RheumNow #ACR22 Abstr#1598 https://t.co/sRKkgkYtQJ https://t.co/YMXMEH3wsq

• Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 In…

Ogdie @AlexisOgdie et al. CorEvitas, PsA treatment after 1st line TNFi failure. Switching MOA probably more effective @RheumNow #ACR22 Abstr#1600 https://t.co/vy8gxDaYxZ https://t.co/NmkESbSNfL

• The Impact of Second-Line Therapeutic on Disease Control After Discontinuation …